Table 4. ST2 Concentration (continuous) and cardiovascular outcomes per log increase in ST2.
30-Day follow-up1-Year follow-up
HR (95% CI)PHR (95% CI)P
All-cause mortality
    Unadjusted1.79 (1.50–2.13)<0.0011.56 (1.41–1.73)<0.001
    Adjusteda1.45 (1.19–1.76)<0.0011.26 (1.12–1.40)<0.001
CVD
    Unadjusted1.74 (1.45–2.10)<0.0011.51 (1.35–1.69)<0.001
    Adjusted1.39 (1.13–1.70)0.0021.19 (1.06–1.34)0.004
New or worsening HF
    Unadjusted1.83 (1.58–2.12)<0.0011.72 (1.54–1.92)<0.001
    Adjusted1.47 (1.25–1.74)<0.0011.37 (1.21–1.55)<0.001
CVD/HF
    Unadjusted1.80 (1.58–2.04)<0.0011.56 (1.43–1.71)<0.001
    Adjusted1.43 (1.24–1.65)<0.0011.25 (1.13–1.38)<0.001